Markku J. Savolainen

Researcher Next ID · RN-007531

Researcher · Medicine

Oulu, Finland

Not currently recruitingFunding unknown

Research interests

Medicine

Biochemistry, Genetics and Molecular Biology

Diabetes, Cardiovascular Risks, and Lipoproteins

Alcohol Consumption and Health Effects

Metabolomics and Mass Spectrometry Studies

Liver Disease Diagnosis and Treatment

Lipoproteins and Cardiovascular Health

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
The Lancet · 2017 · 10.1016/s0140-6736(17)30069-7
Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA
Nature Communications · 2016 · 10.1038/ncomms11122
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
International Journal of Obesity · 2011 · 10.1038/ijo.2011.158
Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma
Nature Genetics · 2011 · 10.1038/ng.970
High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism
The Analyst · 2009 · 10.1039/b910205a

No projects listed.